CRISPR Therapeutics (NASDAQ:CRSP) Releases Earnings Results, Beats Expectations By $0.71 EPS

CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings data on Tuesday. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71, Zacks reports. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

CRISPR Therapeutics Trading Up 0.5 %

CRSP stock traded up $0.21 during mid-day trading on Tuesday, reaching $39.62. The company’s stock had a trading volume of 2,011,960 shares, compared to its average volume of 1,937,955. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10. The business’s 50 day moving average price is $42.45 and its 200 day moving average price is $46.40. The company has a market cap of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. JMP Securities restated a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th. HC Wainwright assumed coverage on CRISPR Therapeutics in a research report on Monday, February 3rd. They set a “buy” rating and a $65.00 price objective for the company. Bank of America dropped their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Chardan Capital restated a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $77.59.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.